APO Research
Talk to an analyst

APO RESEARCH · REPORT

Non-invasive Tumor Detection

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Non-invasive Tumor Detection Market Analysis and Forecast 2026-2032

3 May 2026235 pages

Choose your research edition.

Industry ResearchNon-invasive Tumor Detection Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Non-invasive Tumor Detection Industry Growth and Trends Forecast to 203288 pages · $3,450 USDMarket StructureGlobal Non-invasive Tumor Detection Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032185 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Non-invasive Tumor Detection Market Outlook and Growth Opportunities 2026185 pages · $4,250 USDMarket Analysis & ForecastGlobal Non-invasive Tumor Detection Market Analysis and Forecast 2026-2032235 pages · $4,950 USD

Market perspective

The global Non-invasive Tumor Detection market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Non-invasive Tumor Detection is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Non-invasive Tumor Detection is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Non-invasive Tumor Detection is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Non-invasive Tumor Detection is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Non-invasive Tumor Detection include Datar Cancer Genetics, Nucleix, bioAffinity Technologies, miR Scientific, Nonacus, Natera and Penn Medicine, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Non-invasive Tumor Detection, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Non-invasive Tumor Detection, also provides the revenue of main regions and countries. Of the upcoming market potential for Non-invasive Tumor Detection, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Non-invasive Tumor Detection revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Non-invasive Tumor Detection market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Non-invasive Tumor Detection revenue, projected growth trends, production technology, application and end-user industry.

Non-invasive Tumor Detection Segment by Company

Datar Cancer Genetics

Nucleix

bioAffinity Technologies

miR Scientific

Nonacus

Natera

Penn Medicine

Non-invasive Tumor Detection Segment by Type

DNA

RNA

Non-invasive Tumor Detection Segment by Application

Prostate Cancer

Bladder Cancer

Pancreatic Cancer

Breast Cancer

Gastric Cancer

Others

Non-invasive Tumor Detection Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Non-invasive Tumor Detection market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Non-invasive Tumor Detection and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Non-invasive Tumor Detection.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Non-invasive Tumor Detection in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Non-invasive Tumor Detection company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Non-invasive Tumor Detection revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Non-invasive Tumor Detection Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. DNA Major Player Table 3. RNA Major Player Table 4. Global Non-invasive Tumor Detection Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Prostate Cancer Major Player Table 6. Bladder Cancer Major Player Table 7. Pancreatic Cancer Major Player Table 8. Breast Cancer Major Player Table 9. Gastric Cancer Major Player Table 10. Others Major Player Table 11. Non-invasive Tumor Detection Industry Trends Table 12. Non-invasive Tumor Detection Industry Drivers Table 13. Non-invasive Tumor Detection Industry Opportunities and Challenges Table 14. Non-invasive Tumor Detection Industry Restraints Table 15. Global Non-invasive Tumor Detection Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 16. Global Non-invasive Tumor Detection Market Size by Region (2021-2026) & (US$ Million) Table 17. Global Non-invasive Tumor Detection Market Share by Region (2021-2026) Table 18. Global Non-invasive Tumor Detection Market Size by Region (2027-2032) & (US$ Million) Table 19. Global Non-invasive Tumor Detection Market Share by Region (2027-2032) Table 20. Global Non-invasive Tumor Detection Revenue by Players (US$ Million) & (2021-2026) Table 21. Global Non-invasive Tumor Detection Revenue Market Share by Players (2021-2026) Table 22. Global Non-invasive Tumor Detection Key Players Ranking, 2024 VS 2025 VS 2026 Table 23. Global Non-invasive Tumor Detection Key Players Headquarters & Area Served Table 24. Global Non-invasive Tumor Detection Players, Product Type & Application Table 25. Global Non-invasive Tumor Detection Players Establishment Date Table 26. Global Players Market Concentration Ratio (CR5 and HHI) Table 27. Global Non-invasive Tumor Detection by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 28. Global Non-invasive Tumor Detection Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Non-invasive Tumor Detection Revenue by Type (2021-2026) & (US$ Million) Table 30. Global Non-invasive Tumor Detection Revenue by Type (2027-2032) & (US$ Million) Table 31. Global Non-invasive Tumor Detection Revenue Market Share by Type (2021-2026) Table 32. Global Non-invasive Tumor Detection Revenue Market Share by Type (2027-2032) Table 33. Global Non-invasive Tumor Detection Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Non-invasive Tumor Detection Revenue by Application (2021-2026) & (US$ Million) Table 35. Global Non-invasive Tumor Detection Revenue by Application (2027-2032) & (US$ Million) Table 36. Global Non-invasive Tumor Detection Revenue Market Share by Application (2021-2026) Table 37. Global Non-invasive Tumor Detection Revenue Market Share by Application (2027-2032) Table 38. Datar Cancer Genetics Company Information Table 39. Datar Cancer Genetics Business Overview Table 40. Datar Cancer Genetics Non-invasive Tumor Detection Revenue and Gross Margin (US$ Million) & (2021-2026) Table 41. Datar Cancer Genetics Non-invasive Tumor Detection Product Portfolio Table 42. Datar Cancer Genetics Recent Development Table 43. Nucleix Company Information Table 44. Nucleix Business Overview Table 45. Nucleix Non-invasive Tumor Detection Revenue and Gross Margin (US$ Million) & (2021-2026) Table 46. Nucleix Non-invasive Tumor Detection Product Portfolio Table 47. Nucleix Recent Development Table 48. bioAffinity Technologies Company Information Table 49. bioAffinity Technologies Business Overview Table 50. bioAffinity Technologies Non-invasive Tumor Detection Revenue and Gross Margin (US$ Million) & (2021-2026) Table 51. bioAffinity Technologies Non-invasive Tumor Detection Product Portfolio Table 52. bioAffinity Technologies Recent Development Table 53. miR Scientific Company Information Table 54. miR Scientific Business Overview Table 55. miR Scientific Non-invasive Tumor Detection Revenue and Gross Margin (US$ Million) & (2021-2026) Table 56. miR Scientific Non-invasive Tumor Detection Product Portfolio Table 57. miR Scientific Recent Development Table 58. Nonacus Company Information Table 59. Nonacus Business Overview Table 60. Nonacus Non-invasive Tumor Detection Revenue and Gross Margin (US$ Million) & (2021-2026) Table 61. Nonacus Non-invasive Tumor Detection Product Portfolio Table 62. Nonacus Recent Development Table 63. Natera Company Information Table 64. Natera Business Overview Table 65. Natera Non-invasive Tumor Detection Revenue and Gross Margin (US$ Million) & (2021-2026) Table 66. Natera Non-invasive Tumor Detection Product Portfolio Table 67. Natera Recent Development Table 68. Penn Medicine Company Information Table 69. Penn Medicine Business Overview Table 70. Penn Medicine Non-invasive Tumor Detection Revenue and Gross Margin (US$ Million) & (2021-2026) Table 71. Penn Medicine Non-invasive Tumor Detection Product Portfolio Table 72. Penn Medicine Recent Development Table 73. North America Non-invasive Tumor Detection Revenue by Type (2021-2026) & (US$ Million) Table 74. North America Non-invasive Tumor Detection Revenue by Type (2027-2032) & (US$ Million) Table 75. North America Non-invasive Tumor Detection Revenue by Application (2021-2026) & (US$ Million) Table 76. North America Non-invasive Tumor Detection Revenue by Application (2027-2032) & (US$ Million) Table 77. North America Non-invasive Tumor Detection Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 78. North America Non-invasive Tumor Detection Revenue by Country (2021-2026) & (US$ Million) Table 79. North America Non-invasive Tumor Detection Revenue by Country (US$ Million) & (2027-2032) Table 80. Europe Non-invasive Tumor Detection Revenue by Type (2021-2026) & (US$ Million) Table 81. Europe Non-invasive Tumor Detection Revenue by Type (2027-2032) & (US$ Million) Table 82. Europe Non-invasive Tumor Detection Revenue by Application (2021-2026) & (US$ Million) Table 83. Europe Non-invasive Tumor Detection Revenue by Application (2027-2032) & (US$ Million) Table 84. Europe Non-invasive Tumor Detection Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 85. Europe Non-invasive Tumor Detection Revenue by Country (2021-2026) & (US$ Million) Table 86. Europe Non-invasive Tumor Detection Revenue by Country (US$ Million) & (2027-2032) Table 87. China Non-invasive Tumor Detection Revenue by Type (2021-2026) & (US$ Million) Table 88. China Non-invasive Tumor Detection Revenue by Type (2027-2032) & (US$ Million) Table 89. China Non-invasive Tumor Detection Revenue by Application (2021-2026) & (US$ Million) Table 90. China Non-invasive Tumor Detection Revenue by Application (2027-2032) & (US$ Million) Table 91. Asia Non-invasive Tumor Detection Revenue by Type (2021-2026) & (US$ Million) Table 92. Asia Non-invasive Tumor Detection Revenue by Type (2027-2032) & (US$ Million) Table 93. Asia Non-invasive Tumor Detection Revenue by Application (2021-2026) & (US$ Million) Table 94. Asia Non-invasive Tumor Detection Revenue by Application (2027-2032) & (US$ Million) Table 95. Asia Non-invasive Tumor Detection Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 96. Asia Non-invasive Tumor Detection Revenue by Region (US$ Million) & (2021-2026) Table 97. Asia Non-invasive Tumor Detection Revenue by Region (US$ Million) & (2027-2032) Table 98. SAMEA Non-invasive Tumor Detection Revenue by Type (2021-2026) & (US$ Million) Table 99. SAMEA Non-invasive Tumor Detection Revenue by Type (2027-2032) & (US$ Million) Table 100. SAMEA Non-invasive Tumor Detection Revenue by Application (2021-2026) & (US$ Million) Table 101. SAMEA Non-invasive Tumor Detection Revenue by Application (2027-2032) & (US$ Million) Table 102. SAMEA Non-invasive Tumor Detection Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 103. SAMEA Non-invasive Tumor Detection Revenue by Country (2021-2026) & (US$ Million) Table 104. SAMEA Non-invasive Tumor Detection Revenue by Country (US$ Million) & (2027-2032) Table 105. Research Programs/Design for This Report Table 106. Authors List of This Report Table 107. Secondary Sources Table 108. Primary Sources List of Figures Figure 1. Non-invasive Tumor Detection Image Figure 2. Global Non-invasive Tumor Detection Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Non-invasive Tumor Detection Market Size Share 2021 VS 2025 VS 2032 Figure 4. DNA Image Figure 5. RNA Image Figure 6. Global Non-invasive Tumor Detection Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Non-invasive Tumor Detection Market Size Share 2021 VS 2025 VS 2032 Figure 8. Prostate Cancer Image Figure 9. Bladder Cancer Image Figure 10. Pancreatic Cancer Image Figure 11. Breast Cancer Image Figure 12. Gastric Cancer Image Figure 13. Others Image Figure 14. Global Non-invasive Tumor Detection Market Size (US$ Million) & (2021-2032) Figure 15. Global Non-invasive Tumor Detection Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 16. Global Non-invasive Tumor Detection Market Share by Region: 2021 VS 2025 VS 2032 Figure 17. Global Non-invasive Tumor Detection Players Revenue Share Top 10 and Top 5 in 2025 Figure 18. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 19. Global Non-invasive Tumor Detection Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Non-invasive Tumor Detection Revenue Market Share 2021 VS 2025 VS 2032 Figure 21. Global Non-invasive Tumor Detection Revenue Market Share by Type (2021-2032) Figure 22. Global Non-invasive Tumor Detection Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Non-invasive Tumor Detection Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 24. Global Non-invasive Tumor Detection Revenue Market Share by Application (2021-2032) Figure 25. North America Non-invasive Tumor Detection Revenue YoY Growth (2021-2032) & (US$ Million) Figure 26. North America Non-invasive Tumor Detection Revenue Share by Type (2021-2032) Figure 27. North America Non-invasive Tumor Detection Revenue Share by Application (2021-2032) Figure 28. North America Non-invasive Tumor Detection Revenue Share by Country (2021-2032) Figure 29. United States Non-invasive Tumor Detection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Canada Non-invasive Tumor Detection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Mexico Non-invasive Tumor Detection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Europe Non-invasive Tumor Detection Revenue YoY Growth (2021-2032) & (US$ Million) Figure 33. Europe Non-invasive Tumor Detection Revenue Share by Type (2021-2032) Figure 34. Europe Non-invasive Tumor Detection Revenue Share by Application (2021-2032) Figure 35. Europe Non-invasive Tumor Detection Revenue Share by Country (2021-2032) Figure 36. Germany Non-invasive Tumor Detection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. France Non-invasive Tumor Detection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. U.K. Non-invasive Tumor Detection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Italy Non-invasive Tumor Detection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Spain Non-invasive Tumor Detection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Russia Non-invasive Tumor Detection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Netherlands Non-invasive Tumor Detection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Nordic Countries Non-invasive Tumor Detection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. China Non-invasive Tumor Detection Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. China Non-invasive Tumor Detection Revenue Share by Type (2021-2032) Figure 46. China Non-invasive Tumor Detection Revenue Share by Application (2021-2032) Figure 47. Asia Non-invasive Tumor Detection Revenue YoY Growth (2021-2032) & (US$ Million) Figure 48. Asia Non-invasive Tumor Detection Revenue Share by Type (2021-2032) Figure 49. Asia Non-invasive Tumor Detection Revenue Share by Application (2021-2032) Figure 50. Asia Non-invasive Tumor Detection Revenue Share by Region (2021-2032) Figure 51. Japan Non-invasive Tumor Detection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. South Korea Non-invasive Tumor Detection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. India Non-invasive Tumor Detection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Australia Non-invasive Tumor Detection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Taiwan Non-invasive Tumor Detection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Southeast Asia Non-invasive Tumor Detection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. SAMEA Non-invasive Tumor Detection Revenue YoY Growth (2021-2032) & (US$ Million) Figure 58. SAMEA Non-invasive Tumor Detection Revenue Share by Type (2021-2032) Figure 59. SAMEA Non-invasive Tumor Detection Revenue Share by Application (2021-2032) Figure 60. SAMEA Non-invasive Tumor Detection Revenue Share by Country (2021-2032) Figure 61. Brazil Non-invasive Tumor Detection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Argentina Non-invasive Tumor Detection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Chile Non-invasive Tumor Detection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Colombia Non-invasive Tumor Detection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Peru Non-invasive Tumor Detection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Saudi Arabia Non-invasive Tumor Detection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Israel Non-invasive Tumor Detection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. UAE Non-invasive Tumor Detection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Turkey Non-invasive Tumor Detection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Iran Non-invasive Tumor Detection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Egypt Non-invasive Tumor Detection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • DNA
  • RNA
Applications
  • Prostate Cancer
  • Bladder Cancer
  • Pancreatic Cancer
  • Breast Cancer
  • Gastric Cancer
  • Others
Companies covered
  • Datar Cancer Genetics
  • Nucleix
  • bioAffinity Technologies
  • miR Scientific
  • Nonacus
  • Natera
  • Penn Medicine

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Non-invasive Tumor Detection Market by Type
  3. 1.2.1 Global Non-invasive Tumor Detection Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 DNA
  5. 1.2.3 RNA
  6. 1.3 Non-invasive Tumor Detection Market by Application
  7. 1.3.1 Global Non-invasive Tumor Detection Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Prostate Cancer
  9. 1.3.3 Bladder Cancer
  10. 1.3.4 Pancreatic Cancer
  11. 1.3.5 Breast Cancer
  12. 1.3.6 Gastric Cancer
  13. 1.3.7 Others
  14. 1.4 Assumptions and Limitations
  15. 1.5 Study Goals and Objectives
2 Non-invasive Tumor Detection Market Dynamics
  1. 2.1 Non-invasive Tumor Detection Industry Trends
  2. 2.2 Non-invasive Tumor Detection Industry Drivers
  3. 2.3 Non-invasive Tumor Detection Industry Opportunities and Challenges
  4. 2.4 Non-invasive Tumor Detection Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Non-invasive Tumor Detection Market Perspective (2021-2032)
  2. 3.2 Global Non-invasive Tumor Detection Growth Trends by Region
  3. 3.2.1 Global Non-invasive Tumor Detection Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Non-invasive Tumor Detection Market Size by Region (2021-2026)
  5. 3.2.3 Global Non-invasive Tumor Detection Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Non-invasive Tumor Detection Revenue by Players
  2. 4.1.1 Global Non-invasive Tumor Detection Revenue by Players (2021-2026)
  3. 4.1.2 Global Non-invasive Tumor Detection Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Non-invasive Tumor Detection Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Non-invasive Tumor Detection Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Non-invasive Tumor Detection Key Players Headquarters & Area Served
  7. 4.4 Global Non-invasive Tumor Detection Players, Product Type & Application
  8. 4.5 Global Non-invasive Tumor Detection Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Non-invasive Tumor Detection Market CR5 and HHI
  11. 4.6.3 2025 Non-invasive Tumor Detection Tier 1, Tier 2, and Tier 3
5 Non-invasive Tumor Detection Market Size by Type
  1. 5.1 Global Non-invasive Tumor Detection Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Non-invasive Tumor Detection Revenue by Type (2021-2032)
  3. 5.3 Global Non-invasive Tumor Detection Revenue Market Share by Type (2021-2032)
6 Non-invasive Tumor Detection Market Size by Application
  1. 6.1 Global Non-invasive Tumor Detection Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Non-invasive Tumor Detection Revenue by Application (2021-2032)
  3. 6.3 Global Non-invasive Tumor Detection Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Datar Cancer Genetics
  2. 7.1.1 Datar Cancer Genetics Company Information
  3. 7.1.2 Datar Cancer Genetics Business Overview
  4. 7.1.3 Datar Cancer Genetics Non-invasive Tumor Detection Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Datar Cancer Genetics Non-invasive Tumor Detection Product Portfolio
  6. 7.1.5 Datar Cancer Genetics Recent Developments
  7. 7.2 Nucleix
  8. 7.2.1 Nucleix Company Information
  9. 7.2.2 Nucleix Business Overview
  10. 7.2.3 Nucleix Non-invasive Tumor Detection Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Nucleix Non-invasive Tumor Detection Product Portfolio
  12. 7.2.5 Nucleix Recent Developments
  13. 7.3 bioAffinity Technologies
  14. 7.3.1 bioAffinity Technologies Company Information
  15. 7.3.2 bioAffinity Technologies Business Overview
  16. 7.3.3 bioAffinity Technologies Non-invasive Tumor Detection Revenue and Gross Margin (2021-2026)
  17. 7.3.4 bioAffinity Technologies Non-invasive Tumor Detection Product Portfolio
  18. 7.3.5 bioAffinity Technologies Recent Developments
  19. 7.4 miR Scientific
  20. 7.4.1 miR Scientific Company Information
  21. 7.4.2 miR Scientific Business Overview
  22. 7.4.3 miR Scientific Non-invasive Tumor Detection Revenue and Gross Margin (2021-2026)
  23. 7.4.4 miR Scientific Non-invasive Tumor Detection Product Portfolio
  24. 7.4.5 miR Scientific Recent Developments
  25. 7.5 Nonacus
  26. 7.5.1 Nonacus Company Information
  27. 7.5.2 Nonacus Business Overview
  28. 7.5.3 Nonacus Non-invasive Tumor Detection Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Nonacus Non-invasive Tumor Detection Product Portfolio
  30. 7.5.5 Nonacus Recent Developments
  31. 7.6 Natera
  32. 7.6.1 Natera Company Information
  33. 7.6.2 Natera Business Overview
  34. 7.6.3 Natera Non-invasive Tumor Detection Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Natera Non-invasive Tumor Detection Product Portfolio
  36. 7.6.5 Natera Recent Developments
  37. 7.7 Penn Medicine
  38. 7.7.1 Penn Medicine Company Information
  39. 7.7.2 Penn Medicine Business Overview
  40. 7.7.3 Penn Medicine Non-invasive Tumor Detection Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Penn Medicine Non-invasive Tumor Detection Product Portfolio
  42. 7.7.5 Penn Medicine Recent Developments
8 North America
  1. 8.1 North America Non-invasive Tumor Detection Revenue (2021-2032)
  2. 8.2 North America Non-invasive Tumor Detection Revenue by Type (2021-2032)
  3. 8.2.1 North America Non-invasive Tumor Detection Revenue by Type (2021-2026)
  4. 8.2.2 North America Non-invasive Tumor Detection Revenue by Type (2027-2032)
  5. 8.3 North America Non-invasive Tumor Detection Revenue Share by Type (2021-2032)
  6. 8.4 North America Non-invasive Tumor Detection Revenue by Application (2021-2032)
  7. 8.4.1 North America Non-invasive Tumor Detection Revenue by Application (2021-2026)
  8. 8.4.2 North America Non-invasive Tumor Detection Revenue by Application (2027-2032)
  9. 8.5 North America Non-invasive Tumor Detection Revenue Share by Application (2021-2032)
  10. 8.6 North America Non-invasive Tumor Detection Revenue by Country
  11. 8.6.1 North America Non-invasive Tumor Detection Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Non-invasive Tumor Detection Revenue by Country (2021-2026)
  13. 8.6.3 North America Non-invasive Tumor Detection Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Non-invasive Tumor Detection Revenue (2021-2032)
  2. 9.2 Europe Non-invasive Tumor Detection Revenue by Type (2021-2032)
  3. 9.2.1 Europe Non-invasive Tumor Detection Revenue by Type (2021-2026)
  4. 9.2.2 Europe Non-invasive Tumor Detection Revenue by Type (2027-2032)
  5. 9.3 Europe Non-invasive Tumor Detection Revenue Share by Type (2021-2032)
  6. 9.4 Europe Non-invasive Tumor Detection Revenue by Application (2021-2032)
  7. 9.4.1 Europe Non-invasive Tumor Detection Revenue by Application (2021-2026)
  8. 9.4.2 Europe Non-invasive Tumor Detection Revenue by Application (2027-2032)
  9. 9.5 Europe Non-invasive Tumor Detection Revenue Share by Application (2021-2032)
  10. 9.6 Europe Non-invasive Tumor Detection Revenue by Country
  11. 9.6.1 Europe Non-invasive Tumor Detection Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Non-invasive Tumor Detection Revenue by Country (2021-2026)
  13. 9.6.3 Europe Non-invasive Tumor Detection Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Non-invasive Tumor Detection Revenue (2021-2032)
  2. 10.2 China Non-invasive Tumor Detection Revenue by Type (2021-2032)
  3. 10.2.1 China Non-invasive Tumor Detection Revenue by Type (2021-2026)
  4. 10.2.2 China Non-invasive Tumor Detection Revenue by Type (2027-2032)
  5. 10.3 China Non-invasive Tumor Detection Revenue Share by Type (2021-2032)
  6. 10.4 China Non-invasive Tumor Detection Revenue by Application (2021-2032)
  7. 10.4.1 China Non-invasive Tumor Detection Revenue by Application (2021-2026)
  8. 10.4.2 China Non-invasive Tumor Detection Revenue by Application (2027-2032)
  9. 10.5 China Non-invasive Tumor Detection Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Non-invasive Tumor Detection Revenue (2021-2032)
  2. 11.2 Asia Non-invasive Tumor Detection Revenue by Type (2021-2032)
  3. 11.2.1 Asia Non-invasive Tumor Detection Revenue by Type (2021-2026)
  4. 11.2.2 Asia Non-invasive Tumor Detection Revenue by Type (2027-2032)
  5. 11.3 Asia Non-invasive Tumor Detection Revenue Share by Type (2021-2032)
  6. 11.4 Asia Non-invasive Tumor Detection Revenue by Application (2021-2032)
  7. 11.4.1 Asia Non-invasive Tumor Detection Revenue by Application (2021-2026)
  8. 11.4.2 Asia Non-invasive Tumor Detection Revenue by Application (2027-2032)
  9. 11.5 Asia Non-invasive Tumor Detection Revenue Share by Application (2021-2032)
  10. 11.6 Asia Non-invasive Tumor Detection Revenue by Country
  11. 11.6.1 Asia Non-invasive Tumor Detection Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Non-invasive Tumor Detection Revenue by Country (2021-2026)
  13. 11.6.3 Asia Non-invasive Tumor Detection Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Non-invasive Tumor Detection Revenue (2021-2032)
  2. 12.2 SAMEA Non-invasive Tumor Detection Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Non-invasive Tumor Detection Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Non-invasive Tumor Detection Revenue by Type (2027-2032)
  5. 12.3 SAMEA Non-invasive Tumor Detection Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Non-invasive Tumor Detection Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Non-invasive Tumor Detection Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Non-invasive Tumor Detection Revenue by Application (2027-2032)
  9. 12.5 SAMEA Non-invasive Tumor Detection Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Non-invasive Tumor Detection Revenue by Country
  11. 12.6.1 SAMEA Non-invasive Tumor Detection Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Non-invasive Tumor Detection Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Non-invasive Tumor Detection Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst